arrow
G

Guy Laureys

university hospital ghent
H指数:25
被引数:3,163

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Beyond the cut-off: harmonizing kappa free light chain index using likelihood ratios improves the clinical interpretation in the diagnosis of multiple sclerosis

超越截断值:通过使用似然比调和游离Kappa轻链指数可改善多发性硬化症诊断的临床解释

2025-12-030
OAAI
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease-Modifying Treatments for Multiple Sclerosis

靶向髓鞘再生的干预措施最新进展及对获批多发性硬化疾病修正疗法髓鞘再生效应的系统综述

2025-11-110
OAAI
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Explainable time-to-progression predictions in multiple sclerosis

多发性硬化症可解释的进展时间预测

2025-05-010
PRE
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study

血清阴性NMOSD的进展独立于复发活动和复发相关的恶化:一项国际队列研究

2025-04-140
OA
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
2024-11-012
OAAI
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
2024-09-040
PRE
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

克拉屈滨与芬戈莫德,那他珠单抗,ocrelizumab和阿仑单抗在复发缓解型多发性硬化症中的疗效比较

2024-08-010
PRE